Showing results (1-10 of 148) with videos related to
Sort By:
Pageof 15
Nature Reviews. Urology|November 27, 2013
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agentsLina Yin, Qingzhong HuEuropean Journal of Medicinal Chemistry|September 5, 2020
Chimera induced protein degradation: PROTACs and beyondLina Yin, Qingzhong HuExpert Opinion on Therapeutic Patents|July 26, 2016
Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016)Li Ma, Lina Yin, Qingzhong HuPlos One|November 8, 2012
3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2Lina Yin, Qingzhong Hu, Rolf W HartmannJournal of Medicinal Chemistry|January 16, 2014
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseasesQingzhong Hu, Lina Yin, Rolf W HartmannJournal of Medicinal Chemistry|January 4, 2013
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risksLina Yin, Qingzhong Hu, Rolf W HartmannJournal of Medicinal Chemistry|August 7, 2012
Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancerQingzhong Hu, Lina Yin, Rolf W HartmannInternational Journal of Molecular Sciences|July 25, 2013
Recent progress in pharmaceutical therapies for castration-resistant prostate cancerLina Yin, Qingzhong Hu, Rolf W HartmannJournal of Medicinal Chemistry|June 17, 2010
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitorsQingzhong Hu, Lina Yin, Carsten Jagusch, et al.Drug Discovery Today|January 7, 2023
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitisHaiyan Li, Ting Guan, Shi Qin, et al.Pageof 15